Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 10INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 7Genitourinary 7Breast 5Tumor-Agnostic 4CNS 4Other solid neoplasm 3Head & Neck 3Dermatologic 3Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Carcinoma 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Therapeutics × Tumor-Agnostic × Clear all
NCT05904236 2025-04-08

ICVB-1042

IconOVir Bio

Phase 1 Terminated
17 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02193503 2023-09-28

MVX-ONCO-1 in Patients With Solid Tumor

Maxivax SA

Phase 1 Active not recruiting
34 enrolled
Tumor-Agnostic

Neoplasms

NCT02587819 2016-04-14

Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

Biosceptre

Phase 1 Completed
21 enrolled 9 charts
Tumor-Agnostic

Carcinoma

NCT00874042 2012-07-23

Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
74 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡